Do you or your loved one have Multiple Myeloma that is no longer responding to treatment?

We have a clinical trial for patients who are looking for potential new treatment options. If you have relapsed or refractory Multiple Myeloma you may want to consider participating in the K36-MMSET-001 study.

01

What are clinical studies?

Without clinical studies and the volunteers who participate in these studies no potential new treatments could be developed.

Clinical studies:

- **Find new ways** to prevent, detect or treat conditions.
- **Provide important information** about the safety & effectiveness of potential new medications.
- **Follow standards** and are closely regulated.
- **Are reviewed and monitored** carefully to make sure that the rights of participants are protected, no unnecessary risks are involved and important medical questions are answered.

02

What is the goal of Phase I studies?

Phase I clinical studies include a small number of participants with the condition under study.

The goal of Phase I studies is to find out:

- **How well** the study drug works
- **More about potential side effects** of the study drug
- **A tolerable dose** for the study drug
- **If the study drug will work** for your condition

03

What is the K36-MMSET-001 study?

The K36-MMSET-001 study has been designed to assess the effectiveness and safety of KTX-1001, an investigational* drug for patients with Multiple Myeloma who have limited treatment options.

- **The safest and most effective** dose of KTX-1001 will also be identified during the study.
- **KTX-1001 is a potentially new drug** that blocks a protein that is overexpressed in Multiple Myeloma.

*"Investigational" means the study drug is available for use in clinical research but not yet available for the treatment of Multiple Myeloma.

.

06

Am I eligible?

Eligibility:

- **At least 18** years of age
- **Have a confirmed diagnosis** of relapsed or refractory Multiple Myeloma
- **Have received** at least 3 prior treatments for your Multiple Myeloma

k36 therapeutics

04

What happens at study visits?

At study visits, you will:

- **Have health checks**, including: temperature, blood pressure, pulse, and breathing rate, blood/urine tests, bone marrow samples, and imaging (PET, CT, MRI) to assess your disease.
- **Talk with your study doctor or study team**. They will answer questions you may have.
- **Receive the study drug**, based on part of the study and dose level that your study doctor will provide.
- **Be given a study diary** and instructions on how to complete the diary.
- **Take KTX-1001** by mouth every day.



05

What will happen if I participate?

If you are interested in the study, you will

- **Be given an informed consent form to read and sign:** It will provide you with all study details, including potential risks and benefits. You will be given a chance to ask any questions you might have before signing the form.
- **Complete the screening period:** Study doctors will ask you a number of medical questions. You will have health tests performed to determine if you qualify for this study.

If during the study you change your mind, you are free to leave at any point. During the study, the study drug will be provided to you at no charge.

04

What is the Study Design?

The K36-MMSET-001 study has two part. You will be enrolled into one of the two parts.

- **Dose Escalation Part 1:** Participants will receive KTX-1001 at dose levels based on safety information collected during the study. The dose of KTX-1001 received by participants will increase as more participants receive KTX-1001 and more is learned about how KTX-1001 affects the body.
- **Dose Escalation Part 2:** Participants will receive KTX-1001 at the dose determined to be the most tolerable in Part 1. Part 2 will include participants with specific Multiple Myeloma features.

k36 therapeutics